Additionally, in patients with CLL, Blombery et al. detected simultaneous BCL2 mutations within CLL cells and BAX mutations in the myeloid compartment of the same patients, indicating lineage-specific adaptation to VEN therapy. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.